A new approach to biopharmaceutical manufacturing has landed Neion Bio $11.0M in Seed funding. The startup is applying breakthroughs in genetic engineering and stem cell biology to reinvent the entire production process, developing a platform capable of manufacturing virtually any complex molecule.
This innovative system promises orders of magnitude superior cost, scalability, and resiliency compared to existing methods. Neion Bio's technology aims to fundamentally transform how critical medicines are produced, potentially democratizing access to advanced treatments.













.png&w=3840&q=75)